Приказ основних података о документу

dc.creatorWardlaw, Joanna M
dc.creatorChabriat, Hugues
dc.creatorde Leeuw, Frank-Erik
dc.creatorDebette, Stéphanie
dc.creatorDichgans, Martin
dc.creatorDoubal, Fergus
dc.creatorJokinen, Hanna
dc.creatorKatsanos, Aristeidis H
dc.creatorOrnello, Raffaele
dc.creatorPantoni, Leonardo
dc.creatorPasi, Marco
dc.creatorPavlović, Aleksandra
dc.creatorRudilosso, Salvatore
dc.creatorSchmidt, Reinhold
dc.creatorStaals, Julie
dc.creatorTaylor-Rowan, Martin
dc.creatorHussain, Salman
dc.creatorLindgren, Arne G
dc.date.accessioned2024-02-26T11:32:47Z
dc.date.available2024-02-26T11:32:47Z
dc.date.issued2024
dc.identifier.issn2396-9873
dc.identifier.urihttps://doi.org/10.1177/23969873231219416
dc.identifier.uriinternal-pdf://2338/Wardlaw et al. - 2024 - European stroke organisation (ESO) guideline on ce.pdf
dc.identifier.urihttp://rfasper.fasper.bg.ac.rs/handle/123456789/5408
dc.description.abstractA quarter of ischaemic strokes are lacunar subtype, typically neurologically mild, usually resulting from intrinsic cerebral small vessel pathology, with risk factor profiles and outcome rates differing from other stroke subtypes. This European Stroke Organisation (ESO) guideline provides evidence-based recommendations to assist with clinical decisions about management of lacunar ischaemic stroke to prevent adverse clinical outcomes. The guideline was developed according to ESO standard operating procedures and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. We addressed acute treatment (including progressive lacunar stroke) and secondary prevention in lacunar ischaemic stroke, and prioritised the interventions of thrombolysis, antiplatelet drugs, blood pressure lowering, lipid lowering, lifestyle, and other interventions and their potential effects on the clinical outcomes recurrent stroke, dependency, major adverse cardiovascular events, death, cognitive decline, mobility, gait, or mood disorders. We systematically reviewed the literature, assessed the evidence and where feasible formulated evidence-based recommendations, and expert concensus statements. We found little direct evidence, mostly of low quality. We recommend that patients with suspected acute lacunar ischaemic stroke receive intravenous alteplase, antiplatelet drugs and avoid blood pressure lowering according to current acute ischaemic stroke guidelines. For secondary prevention, we recommend single antiplatelet treatment long-term, blood pressure control, and lipid lowering according to current guidelines. We recommend smoking cessation, regular exercise, other healthy lifestyle modifications, and avoid obesity for general health benefits. We cannot make any recommendation concerning progressive stroke or other drugs. Large randomised controlled trials with clinically important endpoints, including cognitive endpoints, are a priority for lacunar ischaemic stroke.
dc.languageen
dc.publisherSage
dc.relationEuropean Stroke Organisation, Basel, Switzerland.
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.sourceEuropean Stroke Journal
dc.sourceEuropean Stroke Journal
dc.subjectGuideline
dc.subjectsystematic review
dc.subjectstroke
dc.subjectsmall vessel disease
dc.subjectlacunar stroke
dc.subjectalteplase
dc.subjectthrombolysis
dc.subjectantiplatelet
dc.subjectantihypertensive
dc.subjectlipid lowering
dc.titleEuropean stroke organisation (ESO) guideline on cerebral small vessel disease, part 2, lacunar ischaemic stroke
dc.typearticleen
dc.rights.licenseBY-NC
dc.description.versionpublishedVersion
dc.citation.spage23969873231219416
dc.identifier.doi10.1177/23969873231219416
dc.identifier.fulltexthttp://rfasper.fasper.bg.ac.rs/bitstream/id/11112/wardlaw-et-al-2024-european-stroke-organisation-(eso)-guideline-on-cerebral-small-vessel-disease-part-2-lacunar.pdf
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу